ICaPath, Inc.
ICaPath, Inc. is a biotechnology company developing immunotherapy solutions for cancer and serious diseases, with a focus on patent-protected, PLGA-based nanoparticle drug delivery systems. The company's platform enables controlled, sustained-release delivery of cytokines such as interleukin-12, improving immune stimulation while reducing toxicity. This approach is complemented by immune profiling diagnostics for precision medicine, and the company includes expertise spanning biologics manufacturing, translational research, and regulatory advancement for new therapies.
Industries
N/A
ICaPath, Inc.
ICaPath Inc., 714 Venture Drive Suite 191, Morgantown, WV 26058
Products
A platform utilizing PLGA nanoparticles for encapsulation and systemic delivery of biologics and immunotherapeutic agents. Enables controlled drug release, targeted biodistribution, and reduced toxicity.
Immunotherapy product with recombinant interleukin-12 encapsulated in PLGA nanoparticles, delivering sustained low-dose cytokine systemically and activating innate and adaptive immune pathways.
Diagnostic assays using flow cytometry and fluorescent markers (antibodies/dyes) to analyze immune cell subsets and activation states in real-time. Panels evaluate markers including CD3, CD4, CD8, CD56, PD-1, CTLA-4, among others.
A platform utilizing PLGA nanoparticles for encapsulation and systemic delivery of biologics and immunotherapeutic agents. Enables controlled drug release, targeted biodistribution, and reduced toxicity.
Immunotherapy product with recombinant interleukin-12 encapsulated in PLGA nanoparticles, delivering sustained low-dose cytokine systemically and activating innate and adaptive immune pathways.
Diagnostic assays using flow cytometry and fluorescent markers (antibodies/dyes) to analyze immune cell subsets and activation states in real-time. Panels evaluate markers including CD3, CD4, CD8, CD56, PD-1, CTLA-4, among others.
Expertise Areas
- Cancer immunotherapy research
- PLGA-based drug delivery
- Cytokine therapeutics
- Precision medicine
Key Technologies
- PLGA nanoparticles
- Flow cytometry
- Controlled release drug delivery
- Cytokine encapsulation
Key People
Founder, Chairman of the Board, Chief Scientific Officer
Executive Vice Chairman
President
Chief Medical Officer, CMC
Chief Scientific Advisor
Board Member
Founder, Chairman of the Board, Chief Scientific Officer
Executive Vice Chairman
President
Chief Medical Officer, CMC
Chief Scientific Advisor
Board Member
News & Updates
Received an international patent (August 2024) for PLGA-based drug delivery technologies supporting advancements in the delivery of biologics.
Article reporting on anticipated milestone achievements in ICaPath's research pipeline.
Overview of research advances and DNA-related achievements within the company's work-in-progress portfolio.
General article on company progress and updated headlines.
Pre-IND meeting with the FDA resulted in a defined regulatory and strategic pathway for advancing the nanoparticle-based immunotherapy.
International patent covering the PLGA nanoparticle platform for improved pharmacokinetics and drug stability.
Received an international patent (August 2024) for PLGA-based drug delivery technologies supporting advancements in the delivery of biologics.
Article reporting on anticipated milestone achievements in ICaPath's research pipeline.
Overview of research advances and DNA-related achievements within the company's work-in-progress portfolio.
General article on company progress and updated headlines.
Pre-IND meeting with the FDA resulted in a defined regulatory and strategic pathway for advancing the nanoparticle-based immunotherapy.
International patent covering the PLGA nanoparticle platform for improved pharmacokinetics and drug stability.